Bicara Therapeutics (NASDAQ:BCAX) Shares Down 7% – Time to Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares traded down 7% during trading on Monday . The stock traded as low as $16.78 and last traded at $16.6950. 146,545 shares were traded during mid-day trading, a decline of 68% from the average session volume of 455,211 shares. The stock had previously closed at $17.95.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BCAX shares. BTIG Research initiated coverage on Bicara Therapeutics in a report on Thursday. They issued a “buy” rating and a $28.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Monday, November 10th. Wells Fargo & Company increased their price objective on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Tuesday, October 14th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $28.00.

Bicara Therapeutics Price Performance

The stock’s 50-day simple moving average is $16.96 and its two-hundred day simple moving average is $14.16. The firm has a market capitalization of $954.85 million, a P/E ratio of -7.78 and a beta of -0.79.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.12). On average, analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Claire Mazumdar sold 41,163 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $18.86, for a total transaction of $776,334.18. Following the sale, the chief executive officer owned 309,892 shares of the company’s stock, valued at approximately $5,844,563.12. This trade represents a 11.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Ivan Hyep sold 17,795 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $18.55, for a total transaction of $330,097.25. Following the sale, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at approximately $2,696,335.25. This trade represents a 10.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 115,852 shares of company stock worth $2,155,377. Company insiders own 15.50% of the company’s stock.

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors have recently bought and sold shares of the stock. Vestal Point Capital LP lifted its stake in Bicara Therapeutics by 80.6% in the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after purchasing an additional 2,231,025 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Bicara Therapeutics by 2,351.0% in the second quarter. Bank of America Corp DE now owns 451,228 shares of the company’s stock worth $4,192,000 after purchasing an additional 432,818 shares during the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of Bicara Therapeutics in the second quarter worth about $3,742,000. Schroder Investment Management Group lifted its position in shares of Bicara Therapeutics by 921.0% in the second quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock worth $3,951,000 after buying an additional 383,681 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. purchased a new position in Bicara Therapeutics during the 2nd quarter valued at approximately $3,185,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.